| Literature DB >> 32957571 |
Ilenia Bazzucchi1, Federica Patrizio1, Roberta Ceci2, Guglielmo Duranti2, Stefania Sabatini2, Paolo Sgrò3, Luigi Di Luigi3, Massimo Sacchetti1.
Abstract
This study was aimed at investigating whether quercetin (Q) may improve the recovery of neuromuscular function and biochemical parameters in the 7 days following an eccentric exercise-induced muscle damage (EEIMD). Sixteen men (25.9 ± 3.3 y) ingested Q (1000 mg/day) or placebo (PLA) for 14 days following a double-blind crossover study design. A neuromuscular (NM) test was performed pre-post, 24 h, 48 h, 72 h, 96 h and 7 days after an intense eccentric exercise. The force-velocity relationship of the elbow flexor muscles and their maximal voluntary isometric contraction (MVIC) were recorded simultaneously to the electromyographic signals (EMG). Pain, joint angle, arm circumference, plasma creatine kinase (CK) and lactate-dehydrogenase (LDH) were also assessed. The results showed that Q supplementation significantly attenuated the strength loss compared to PLA. During the recovery, force-velocity relationship and mean fibers conduction velocity (MFCV) persisted significantly less when participants consumed PLA rather than Q, especially at the highest angular velocities (p < 0.02). A greater increase in biomarkers of damage was also evident in PLA with respect to Q. Q supplementation for 14 days seems able to ameliorate the recovery of eccentric exercise-induced weakness, neuromuscular function impairment and biochemical parameters increase probably due to its strong anti-inflammatory and antioxidant action.Entities:
Keywords: DOMS; elbow flexors; electromyography; muscle damage; muscle weakness
Mesh:
Substances:
Year: 2020 PMID: 32957571 PMCID: PMC7551500 DOI: 10.3390/nu12092850
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Diagram of the research design. BASELINE: baseline measurements before treatment; PRE: pre-test; MVC: maximal voluntary contraction; POST: post-test; PLA: placebo; Q: quercetin.
Figure 2Torque (a) and mean fibers conduction velocity (MFCV) (b) of the maximal voluntary isometric contraction (MVIC) test in quercetin (Q) and placebo (PLA) before, after the eccentric exercise-induced muscle damage (EEIMD) and during the recovery. Data are expressed as % MVICBASE; mean ± SD; * ≠ from Q p < 0.05.
MFCV in Q and PLA conditions before, after the EEIMD and during the recovery at the different angular velocities of the FV task.
| MFCV (%) | |||||
|---|---|---|---|---|---|
| 30°/s | 60°/s | 120°/s | 240°/s | ||
| PRE | Q | 100.4 ± 5.3 | 101.5 ± 4.9 | 101.7 ± 5.1 | 102.5 ± 6.2 |
| PLA | 100.9 ± 7.4 | 101.0 ± 4.8 | 101.1 ± 4.6 | 101.2 ± 5.9 | |
| POST | Q | 97.1 ± 7.2 | 97.2 ± 8.0 | 97.2 ± 7.4 | 98.3 ± 7.4 |
| PLA | 96.2 ± 9.2 | 96.6 ± 7.3 | 90.2 ± 9.1 * | 87.8 ± 7.7 * | |
| 24 h | Q | 95.9 ± 9.5 | 96.0 ± 9.0 | 96.7 ± 8.0 | 97.2 ± 8.1 |
| PLA | 96.2 ± 5.4 | 97.2 ± 5.7 | 89.8 ± 7.7 * | 86.6 ± 8.5 * | |
| 48 h | Q | 98.2 ± 9.9 | 98.9 ± 8.1 | 98.8 ± 7.5 | 99.1 ± 7.8 |
| PLA | 97.6 ± 6.1 | 97.6 ± 4.4 | 91.8 ± 5.0 * | 89.1 ± 7.9 * | |
| 72 h | Q | 99.5 ± 7.8 | 100.0 ± 7.3 | 99.8 ± 6.3 | 100.9 ± 6.6 |
| PLA | 98.6 ± 3.6 | 97.2 ± 4.3 | 91.4 ± 5.3 | 87.4 ± 6.0 * | |
| 96 h | Q | 99.6 ± 7.1 | 100.2 ± 6.6 | 100.7 ± 5.4 | 100.6 ± 5.5 |
| PLA | 97.0 ± 4.8 | 97.6 ± 4.1 | 92.3 ± 4.8 * | 88.7 ± 6.4 * | |
| 7 d | Q | 100.7 ± 7.8 | 101.2 ± 6.4 | 101.1 ± 5.9 | 102.0 ± 6.2 |
| PLA | 99.3 ± 4.6 | 100.2 ± 3.4 | 93.6 ± 4.4 * | 90.8 ± 5.9 * | |
Data are expressed as % MFCVBASE; mean ± SD; * ≠ from Q p < 0.05. MFCV: mean fibers conduction velocity; Q: quercetin; PLA: placebo; PRE: pre-test; POST: post-test; EEIMD: eccentric exercise-induced muscle damage; FV: Force–velocity
Figure 3Force–velocity (FV) relationship in Q (a) and PLA (b) conditions before (PRE) and after the EEIMD (POST, 72 h, 96 h). Mean ± SD * ≠ from PLA p < 0.05.
Arm circumference, visual analogue scale (VAS) of perceived pain and elbow angle in Q and PLA before, after the EEIMD and during the recovery.
| Arm Circumference | VAS | Elbow Angle | ||
|---|---|---|---|---|
| cm | cm | degrees | ||
| BASELINE | Q | 31.1 ± 0.7 | 0 | 175.3 ± 5.0 |
| PLA | 30.6 ± 0.7 | 0 | 175.0 ± 6.3 | |
| PRE | Q | 31.1 ± 0.7 | 0 | 174.3 ± 5.1 |
| PLA | 30.7 ± 0.8 | 0 | 175.6 ± 7.3 | |
| POST | Q | 32.2 ± 0.7 | 0.4 ± 0.2 | 164.7 ± 6.9 |
| PLA | 32.2 ± 0.8 | 1.2 ± 0.4 | 158.8 ± 14.4 * | |
| 24 h | Q | 31.7 ± 0.6 | 1.7 ± 0.3 | 163.1 ± 8.5 |
| PLA | 31.7 ± 0.8 | 2.8 ± 0.5 | 158.8 ± 13.2 | |
| 48 h | Q | 31.7 ± 0.7 | 2.8 ± 0.5 | 158.1 ± 9.8 |
| PLA | 31.6 ± 0.8 | 3.0 ± 0.5 | 159.1 ± 12.8 | |
| 72 h | Q | 31.4 ± 0.7 | 2.5 ± 0.6 | 160.0 ± 12.1 |
| PLA | 32.0 ± 0.8 | 3.3 ± 0.6 | 155.9 ± 15.6 | |
| 96 h | Q | 31.7 ± 0.7 | 2.8 ± 0.5 | 164.4 ± 11.8 |
| PLA | 31.6 ± 0.8 | 3.0 ± 0.5 | 157.8 ± 12.9 | |
| 7 d | Q | 31.4 ± 0.7 | 2.5 ± 0.6 | 169.7 ± 9.7 |
| PLA | 32.0 ± 0.8 | 3.3 ± 0.6 | 168.1 ± 13.3 | |
Mean ± SD; * ≠ from Q p < 0.05. Q: quercetin; PLA: placebo; PRE: pre-test; POST: post-test.
Figure 4Lactate-dehydrogenase (LDH) (a) and creatine kinase (CK) (b) in Q and PLA before, after the EEIMD and during the recovery. Mean ± SD; * ≠ from Q p < 0.05.